Levetiracetam

Levetiracetam has a unique mechanism unlike any other anticonvulsant. It binds to synaptic vesicle protein 2A (SV2A), a protein involved in neurotransmitter vesicle exocytosis ^{[1, 3]}.

SV2A is present on presynaptic nerve terminals throughout the brain. By modulating SV2A, levetiracetam appears to reduce excessive neurotransmitter release during abnormal, synchronized neuronal activity (seizures) while having minimal effect on normal neurotransmission ^{[1, 3, 4]}.

This unique mechanism accounts for levetiracetam's distinguishing characteristics: it has broad-spectrum antiseizure activity, very few drug interactions (it does not affect CYP450 enzymes or protein binding), and a side effect profile quite different from traditional anticonvulsants ^{[1, 3]}.

Levetiracetam may also have neuroprotective properties through mechanisms including modulation of intracellular calcium transients and antagonism of zinc and beta-carbolines at GABA and glycine receptors ^{[3, 4]}.

Its efficacy across multiple seizure types — focal seizures, primary generalized tonic-clonic seizures, and myoclonic seizures — has been demonstrated in multiple randomized controlled trials. It is now one of the most prescribed anticonvulsants worldwide due to its efficacy, favorable drug interaction profile, and availability of IV formulation for emergency settings ^{[1, 4, 5]}.

Days 1-7: Start at 500 mg twice daily (or 1000 mg/day). Drowsiness and dizziness are the most common early side effects. These are usually mild and improve over 1-2 weeks ^[1].

Weeks 1-4: Dose may be increased to 1000 mg twice daily if needed. Behavioral side effects may emerge — irritability, mood changes, and occasionally frank aggression ("Keppra rage"). This occurs in approximately 10-15% of patients and is more common in patients with a psychiatric history ^{[1, 3, 6]}.

Weeks 4-12: Most patients are on their stable dose (1000-3000 mg/day). Seizure control is typically evident. If behavioral side effects occur, they usually emerge within the first few months ^[1].

Long-term: Levetiracetam is generally well tolerated long-term. It is weight-neutral, has no hepatotoxicity, and requires no routine blood level monitoring (unlike valproate, carbamazepine, and phenytoin). This simplicity is a major practical advantage ^{[1, 4]}.

Levetiracetam can be taken with or without food. Food does not affect absorption ^[1].

Alcohol: Alcohol should be avoided or limited. Both are CNS depressants, and the combination increases drowsiness. Alcohol also lowers the seizure threshold, which can counteract levetiracetam's antiseizure effects ^[1].

Grapefruit: No interaction. Levetiracetam is not metabolized by CYP enzymes ^[1].

Caffeine: No significant interaction ^[1].

Levetiracetam has one of the cleanest food and drug interaction profiles of any anticonvulsant. It is not metabolized by CYP450 enzymes, has minimal protein binding, and is primarily renally excreted unchanged. This makes it one of the easiest anticonvulsants to combine with other medications ^{[1, 3]}.

Focal seizures (adults): Start 500 mg twice daily. Increase by 500 mg twice daily every 2 weeks. Target: 1000-3000 mg/day. Maximum: 3000 mg/day ^[1].

Primary generalized tonic-clonic seizures (adults): Start 500 mg twice daily. Target: 3000 mg/day ^[1].

Myoclonic seizures (adults): Start 500 mg twice daily. Target: 3000 mg/day ^[1].

Extended-release (Keppra XR): 1000 mg once daily. Increase by 1000 mg every 2 weeks. Maximum: 3000 mg/day. Swallow whole; do not crush ^[1].

Pediatric: Dosing based on weight (mg/kg). See prescribing information for age-specific dosing ^[1].

Renal impairment: Dose reduction required based on CrCl. Supplemental dose after hemodialysis ^[1].

IV administration: 15-minute infusion. Bioequivalent to oral. Used when oral is not possible ^[1].

Discontinuation: Taper over 2-4 weeks. Abrupt discontinuation may increase seizure frequency ^[1].

Generic levetiracetam is one of the most affordable anticonvulsants, costing approximately $8-20/month compared to $400-800/month for brand-name Keppra ^[1].

Pharmacy discount programs: Generic levetiracetam is on most $4 generic lists at major retailers. GoodRx prices are typically $5-15/month ^[1].

Solution formulation: The oral solution may be more expensive than tablets but is useful for patients who cannot swallow tablets ^[1].

Insurance: Generic levetiracetam is Tier 1 on virtually all formularies. No prior authorization required ^[1].

IV formulation: Generic IV levetiracetam is available and significantly less expensive than brand Keppra IV ^[1].

Pregnancy: Levetiracetam is considered one of the safer anticonvulsants in pregnancy. Data from multiple pregnancy registries show a major malformation rate of approximately 2.4% with monotherapy — not significantly different from the background rate ^{[1, 8, 9]}. It does not carry the neural tube defect risk of valproate. Levetiracetam clearance increases during pregnancy (up to 50-60%), often requiring dose increases. Folate supplementation (0.4-1 mg/day) is recommended ^{[8, 9]}.

Breastfeeding: Levetiracetam passes into breast milk. The relative infant dose is approximately 3-8% of the maternal weight-adjusted dose. Clinical experience has generally been reassuring, with no consistent adverse effects reported in breastfed infants. Breastfeeding is generally considered compatible ^{[8, 9]}.

Bioequivalence: Generic levetiracetam tablets, oral solution, and XR tablets are FDA AB-rated as bioequivalent to brand Keppra ^[1].

Clinical equivalence: Generic formulations are therapeutically equivalent. As with all anticonvulsants, maintaining consistency with a single manufacturer is recommended when possible ^[1].

Cost: Brand Keppra: $400-800/month. Generic levetiracetam: $8-20/month ^[1].